– USA, CA – Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the appointment of Mary Ann Gray, Ph.D. to the Company’s Board of Directors effective immediately. Dr. Gray will be listed in Galena’s 2016 Proxy and will be a nominee for election, at the Company’s Annual Meeting of Stockholders.
Dr. Gray has an extensive background both as a scientist as well as an analyst and portfolio manager for more than $1 billion in healthcare investments. She is an experienced corporate director for both public and private companies encompassing every stage of development from pre-clinical to commercial. Among her attributes, Dr. Gray combines financial acumen, serving as an audit committee chair for several companies, and has robust experience helping companies navigate the transition from clinical-stage to commercial-ready.
“We are delighted to welcome Mary Ann Gray to our Board of Directors where her scientific background, positions at leading pharmaceutical companies and institutions, and her buy-side and sell-side experience will have an invaluable impact on the success of Galena,” stated Mark W. Schwartz, Ph.D., President and Chief Executive Officer. “Dr. Gray is our first female board member, adding new perspectives to our Board as we continue to expand our portfolio of women’s oncology indications. She has been a champion of NeuVax™ for many years, and we look forward to her guidance and expertise as we advance our programs.”
Dr. Gray is President of Gray Strategic Advisors, LLC, which provides strategic advice to both public and private biotechnology companies. Previously, she spent three and a half years with the Federated Kaufmann Fund focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell-side biotechnology analyst for nine years with Raymond James, Warburg Dillon Read, and Kidder Peabody. Earlier in her career, Dr. Gray held scientific positions at Schering Plough and NeoRx, managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute, and worked in a hospital laboratory.
Dr. Gray currently serves on the board of directors of several publicly traded biotechnology companies. At Acadia Pharmaceuticals she serves as chairman of the audit committee and on the compensation committee. At TetraLogic, Inc. and Juniper Pharmaceuticals she is chair of the respective audit committees, and at Senomyx, Inc., she is chair of the compensation committee and is a member of the audit committee. Previously, Dr. Gray also served on the boards of Dyax Corp., GTC Biotherapeutics, Inc., Telik, and Apthera, Inc. (private). Dr. Gray has a Ph.D. in Pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer, and she received her B.S. in biology from the University of South Carolina. She completed her postdoctoral work at Northwestern University Medical School and Yale University School of Medicine.
“Since my academic career, I have maintained a focus in oncology, and I am thrilled to bring this passion to Galena as a member of the Board of Directors. As a long-term shareholder in the Company, I have believed in NeuVax for over seven years and have closely monitored its development from an early stage asset to its now significantly expanded portfolio of clinical trials. I am grateful for this opportunity to join the company at this critical time as NeuVax is approaching its pivotal endpoint,” added Mary Ann Gray, Ph.D.
“In addition to her work experience, Dr. Gray has played critical roles on the audit and compensation committees of the public biotechnology boards on which she serves. We welcome her broad array of skill sets to enrich the knowledge and depth of our board,” concluded Sanford J. Hillsberg, Chairman of the Board, Galena Biopharma.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.